PTC’s Peltz to retire
Plus: CFO Carlson to depart MiMedx and an update from Beyond Air
PTC Therapeutics Inc. (NASDAQ:PTCT) announced the retirement of Stuart Peltz, who has served as CEO of the rare disease company since its founding in 1998. Peltz will serve as a senior consultant to PTC and join its scientific advisory board. He is succeeded as CEO by COO Matthew Klein, who joined PTC in 2019 from BioElectron Technology Corp. where he was CEO and CMO. Peltz helped pioneer RNA-directed drug development and led PTC from a research organization to a commercial-stage pharmaceutical company with half a dozen products, including Duchenne muscular dystrophy therapy Translarna ataluren.
MiMedx Group Inc. (NASDAQ:MDXG) is looking for a successor to CFO Peter Carlson, who is leaving the placental biologics company to pursue other opportunities. Carlson will assist MiMedx with its search. ...